 | | Vol. 10.31 – 10 August, 2022 |
| |
|
|
| The authors showed that CRISPR–Cas9-mediated deletion of a transposable element — namely the LINE-1 retrotransposon Lx9c11 — in mice resulted in an exaggerated and lethal immune response to virus infection.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers described the development and application of a 3D-printed lab-on-a-chip that concurrently detected, via multiplexed electrochemical outputs and within two hours, SARS-CoV-2 RNA in saliva as well as anti-SARS-CoV-2 immunoglobulins in saliva spiked with blood plasma.
[Nature Biomedical Engineering] |
|
|
|
| Scientists showed that vaccine-elicited CD8+ T cells contributed substantially to virologic control following SARS-CoV-2 challenge in rhesus macaques.
[Science Immunology] |
|
|
|
| The authors indicated that cell surface nucleocapsid protein manipulated innate immunity by sequestering chemokines and could be targeted by Fc-expressing innate immune cells.
[Science Advances] |
|
|
|
| Investigators showed that spike-specific CD8+ T cells were activated and expanded in all analyzed individuals receiving the third and fourth COVID-19 mRNA vaccine shots.
[Nature Communications] |
|
|
|
| Scientists demonstrated that vaccinated subjects made CD4+ T cell responses after one and two doses of NVX-CoV2373, and a subset of individuals made CD8+ T cell responses.
[Journal of Clinical Investigation] |
|
|
|
| Researchers applied a genomic DNA-based approach to concurrently study the immunoglobulin-heavy and T cell receptor β and δ chain loci of 95 individuals.
[Proceedings of the National Academy of Sciences of the United States of America] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| The authors used a high-throughput systems serology approach to profile the biophysical and functional features of serum antibodies induced by PCV13 and PPSV23 at one month and one year.
[Science Translational Medicine] |
|
|
|
| Whole neuron reconstructions from mice infected with parasites that triggered neuron green fluorescent protein expression only after full invasion revealed that ~50% of these T. gondii-invaded neurons no longer harbored parasites.
[Nature Communications] |
|
|
|
| Using an in vitro co-culture model, researchers assessed the effects of Lactobacillus crispatus and G. vaginalis on the cervicovaginal epithelial barrier, the immune mediators that could be contributing to decreased barrier integrity and the immune signaling pathways regulating the immune response.
[Microbiome] |
|
|
|
| Exposing infected human bladder epithelial cells to L. crispatus in vitro markedly reduced the intracellular uropathogenic Escherichia coli load.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists studied the parasitic wasp Leptopilina boulardi (Lb) and its host Drosophila melanogaster. Results showed that Lb successfully developed in conventional hosts with a gut microbiota but failed to develop in axenic hosts without gut microbiota.
[ISME Journal] |
|
|
|
| Investigators determined if heterologous HIV envelope (Env) immunization of SHIV.C.CH505-infected, antiretroviral therapy-suppressed female rhesus macaques could boost autologous Env-specific antibodies.
[NPJ Vaccines] |
|
|
|
|
| The authors provide an overview of the availability of existing literature on immune response and long‐term clinical outcomes after COVID‐19 vaccination.
[Cochrane Database of Systematic Reviews] |
|
|
|
| Scientists analyze clinical outcomes following SARS-CoV-2 infection, as well as response to COVID-19 vaccines in patients with inborn errors of immunity.
[Physiology] |
|
|
|
| Investigators focus on the non-spike mutations of Omicron, especially in its widely circulating subvariants.
[Microbial Pathogenesis] |
|
|
|
|
| Novavax, Inc. announced the initiation of its Phase IIb/III Hummingbird™ global clinical trial. The trial will evaluate the safety and efficacy of two doses of the Novavax COVID-19 vaccine in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series.
[Novavax, Inc.] |
|
|
|
| Injectable antiviral cabotegravir provides stronger protection than an oral pill, but researchers fear it could be too expensive to make a difference for countries with the greatest disease burden.
[Nature News] |
|
|
|
| The pressure is on for Moderna to step up and save the day with a monkeypox vaccine, just as it did for COVID-19. But executives from the famed biotech insist the idea is still in the conceptual phase.
[Fierce Biotech] |
|
|
|
|
| October 26 – 29, 2022
Brussels, Belgium |
|
|
|
|
|
| | University Hospital Cologne – Cologne, Germany |
|
|
|
| | Dalla Lana School of Public Health – Toronto, Ontario, Canada |
|
|
|
| | King’s College London – London, United Kingdom |
|
|
|
| | University of Wisconsin-Madison – Madison, Wisconsin, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
